Every 424B that NYXOAH S A (NYXH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NYXH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NYXH filings page.
Nyxoah is offering 55,232,558 ordinary shares pursuant to a prospectus supplement dated June 5, 2026. The public offering price is €1.48 per share (equivalent to $1.72 per share), with estimated net proceeds of $88.5 million (€76.3 million), and an underwriter option to purchase an additional 8,284,883 ordinary shares to cover over-allotments for 30 days.
The offering would increase shares outstanding from 43,662,403 as of March 31, 2026 to 98,894,961 ordinary shares immediately after the offering (or 107,179,844 if the underwriters exercise the full option). Net proceeds are allocated principally to U.S. commercialization, R&D for Genio system upgrades and manufacturability, international commercialization, clinical data and general corporate purposes.
Nyxoah SA is offering ordinary shares pursuant to this preliminary prospectus supplement, with underwriters granted a 30-day option to purchase additional shares to cover over-allotments. The company reported 43,662,403 ordinary shares outstanding as of March 31, 2026 and stated cash, cash equivalents and financial assets of €25.9 million as of March 31, 2026. The prospectus supplement describes use of proceeds to expand U.S. commercialization, fund R&D and manufacturing initiatives, advance international commercialization and for general corporate purposes. Recent developments disclosed a leadership transition process to appoint a U.S.-based CEO and an expected draw of €13.8 million from the second tranche of a European Investment Bank loan in Q2 2026. The filings also describe ongoing patent litigation and inter partes review proceedings with Inspire Medical Systems and the consolidation of related Delaware actions by the court.
Nyxoah SA is offering 1,215,964 ordinary shares at $4.6304 (€4.00) per share, raising gross proceeds of about $5.6 million and estimated net proceeds of $5.5 million (€4.8 million). The shares are sold directly to investors without an underwriter, and trade on Nasdaq and Euronext Brussels under “NYXH.” Nyxoah plans to use the cash to support the U.S. launch and international commercialization of its Genio system for obstructive sleep apnea, fund clinical data generation and physician-led studies, advance R&D, build a pipeline in OSA monitoring and diagnostics, and for general corporate purposes.
Alongside this deal, the company has arranged a €17.0 million private placement of 4,265,714 ordinary shares at €4.00 and a separate offering of up to €45.0 million in amortizing senior unsecured convertible notes, expected to yield about €41.4 million in gross proceeds. As of September 30, 2025, Nyxoah had 37,544,782 ordinary shares outstanding, which would increase to 38,760,746 after this offering, before giving effect to the private placement, notes conversion, or warrant exercises.